Neurocognitive Assessment and detection of Stroke in Patients Diagnosed with Sickle Cell Disease: Neuropsychological Functioning and Magnetic Resonance Imaging (MRI)
Presenter: E. Vichinsky
Presenter's Affiliation: Children's Hospital, Oakland, California
Type of Session: Scientific
Children who have sickle cell disease(SCD) are at risk for the development stroke or silent infarct, often resulting in cognitive impairment.
It has been estimated that approximately 25% of all children with SCD will have a stroke or silent infarct.
The aim of the current study is to assess the neuropsychological functioning of children with SCD and evaluate them radiographically with MRI.
Materials and Methods
70 children with SCD were evaluated, 29 females and 41 males
Median age was 13 years
Testing included Wechsler Intelligence Test for Children, as well as tests for spatial reasoning, and manual dexterity.
24% (n=17) experienced a stroke, 16% (n=11) had silent infarcts (normal exam with a positive MRI), 60% (n=42) had no stroke.
The most common sites of infarct were frontal lobe (42%) and parietal lobe (29%).
Children without evidence of stroke (MRI or clinically) performed in the average range of normal on all tests.
Those children with evidence of silent infarct had below average scores (compared to the no-stroke group) on the IQ verbal and performance scales, particularly in the areas of math and numerical conceptualization.
Children with evidence of stroke had significantly lower cognitive scores and achievement scores compared to the no-stroke group.
There is a need to further investigate neurocognitive functioning in children SCD. Recognition of their specific needs will allow for the development of comprehensive treatment plans appropriately suited for each child.
This article highlights the importance of identifying neurocognitive deficits in a population of children that might otherwise be simply classified as underachievers. With the understanding of these issues parents, educators, and mental health professionals will be better able to serve these patents.
Oncolink's ASH Coverage made possible by an unrestricted Educational Grant from Amgen.